Study details
Enrolling now
Pregabalin Plus Lofexidine for Opioid Withdrawal
University of Pennsylvania
NCT IDNCT05995535ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
150
Study length
about 2.7 years
Ages
18+
Locations
2 sites in MD, PA
About this study
This trial is testing whether lofexidine plus pregabalin helps manage opioid withdrawal symptoms in adults. Participants will receive either lofexidine/pregabalin or a placebo, and may be offered extended-release injectable naltrexone after completing the withdrawal period.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take LFX/PGB
- 2.Take LFX/PLA-PGB
PhasePhase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Body systems
Psychiatry / Mental Health